Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Valeo Pharma Inc. (C:VPH)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for VPH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 21, 2022 16:13 ET
VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE
Valeo's President and Chief Operating Officer steps down and will continue as special advisor and member of the Board of DirectorsMONTREAL, Nov. 21, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Frederic Fasano has stepped down as Valeo's President and Chief Operating Officer. Mr. Fasano will continue to act as special advisor to the Company and will remain on the Board of Directors. Mr. Fasano's duties and responsibilities are being integrated and assumed by the Company's CEO
Read full article
Nov 15, 2022 06:00 ET
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE
Q4-2022 revenue guidance raised to a record $12.5M - $13.0MFiscal 2022 revenue guidance increased to a record $27.5M - $28.0MMONTREAL, Nov. 15, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company") a Canadian pharmaceutical company, today announced that it has raised revenue guidance for its fourth quarter of 2022 to $12.5 - $13.0 million, an increase of 14% to 18% over previously issued guidance of $11 million. The Company is also increasing its fiscal 2022 revenue guidance to $27.5 – 28.0 million, a forecasted increase exceeding 100% compared
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.54
--
--
Price to Sales - TTM
2.81
5.08
3.57
Price to Book - most recent quarter
--
1.69
1.69
Price to Cash Flow per share - TTM
--
4.57
8.89
Price to Free Cash Flow per share - TTM
--
8.16
12.77
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 196900
Dec 31, 196900
Dec 31, 196900
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Valeo Pharma Inc. is a Canada-based specialty pharmaceutical company. The Company acquires or in-licenses brand and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology, specialty products, hospital generic division. Its respiratory/allergy products include Enerzair, Breezhaler, Atectura, Breezhaler and Allerject. Its ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis, Hesperco and Ametop Gel 4%. Its hospital generic division includes Benztropine, Ethacrynate Sodium and Amikacin. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

See business summary

 

Twitter

Search (past week) for $VPH.CA

  • No tweets found